SDF-1 Binding Nucleic Acids

Abstract

The present invention is related to a nucleic acid molecule, preferably binding to SDF-I, selected from the group comprising type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ. ID. No. 142, SEQ. ID. No. 143 and SEQ. ID. No. 144.

1 . A nucleic acid molecule that binds SDF-1, selected from the group consisting of a type A nucleic acid molecule, a type B nucleic acid molecule, a type C nucleic acid molecule, SEQ ID NO:142, SEQ ID NO:143 and SEQ ID NO:144. 
     
     
         2 . The nucleic acid molecule according to  claim 1 , whereby the type A nucleic acid molecule comprises the following core nucleotide sequence: 
       
         
           
                 
                 
               
                     
                   (SEQ ID NO: 19) 
                 
                     
                   5′ AAAGYRACAHGUMAAX A UGAAAGGUARC 3′ 
                 
             
                
                
               
            
           
         
         whereby X A  is either absent or is A. 
       
     
     
         3 . (canceled) 
     
     
         4 . The nucleic acid molecule according to  claim 1 , wherein the nucleic acid molecule comprises in 5′→3′ direction a first stretch of nucleotides, the core nucleotide sequence, and a second stretch of nucleotides; or a second stretch of nucleotides, the core nucleotide sequence, and a first stretch of nucleotides. 
     
     
         5 . (canceled) 
     
     
         6 . The nucleic acid molecule according to  claim 4 , wherein said first and said second stretches of nucleotides hybridize with each other to form a double-stranded structure. 
     
     
         7 . The nucleic acid molecule according to  claim 6 , wherein said double-stranded structure consists of four to six base pairs or five base pairs. 
     
     
         8 .- 11 . (canceled) 
     
     
         12 . The nucleic acid molecule according to  claim 1 , whereby the type B nucleic acid molecule comprises the following core nucleotide sequence: 
       
         
           
                 
                 
               
                     
                   (SEQ ID NO: 57) 
                 
                     
                   5′ GUGUGAUCUAGAUGUADWGGCUGWUCCUAGUYAGG 3′. 
                 
             
                
                
               
            
           
         
       
     
     
         13 - 22 . (canceled) 
     
     
         23 . The nucleic acid molecule according to  claim 1 , whereby the type C nucleic acid molecule comprises a core nucleotide sequence of GGUYAGGGCUHRX A AGUCGG (SEQ ID NO:90), whereby X A  is either absent or is A. 
     
     
         24 .- 27 . (canceled) 
     
     
         28 . The nucleic acid molecule according to  claim 4 , wherein said first stretch and said second stretch each is individually and independently 0 to 17 nucleotides, 4 to 10 nucleotides or 4 to 6 nucleotides. 
     
     
         29 . The nucleic acid molecule according to  claim 6 , wherein said double-stranded structure comprises 4 to 10 base pairs, 4 to 6 base pairs or 5 base pairs. 
     
     
         30 . The nucleic acid molecule according to  claim 6 , wherein said double-stranded structure comprises 4 to 10 consecutive base pairs, 4 to 6 consecutive base pairs or 5 consecutive base pairs. 
     
     
         31 .- 39 . (canceled) 
     
     
         40 . The nucleic acid molecule according to  claim 1 , wherein said nucleic acid molecule is an antagonist to SDF-1. 
     
     
         41 . The nucleic acid molecule according to  claim 1 , wherein said nucleic acid molecule is an antagonist of an SDF-1 receptor system. 
     
     
         42 . The nucleic acid molecule according to  claim 1 , wherein said SDF-1 is a human SDF-1. 
     
     
         43 . (canceled) 
     
     
         44 . The nucleic acid molecule according to  claim 1 , wherein the nucleic acid molecule comprises a modification. 
     
     
         45 . The nucleic acid according to  claim 44 , wherein said modification comprises a HES moiety or a PEG moiety. 
     
     
         46 .- 47 . (canceled) 
     
     
         48 . The nucleic acid according to  claim 1 , wherein nucleotides of the nucleic acid molecule are L-nucleotides. 
     
     
         49 . A pharmaceutical composition comprising said nucleic acid molecule according to  claim 1  and optionally a further constituent selected from the group consisting of pharmaceutically acceptable excipients and pharmaceutically active agents. 
     
     
         50 .- 55 . (canceled) 
     
     
         56 . A complex comprising SDF-1 and said nucleic acid molecule according to  claim 1 . 
     
     
         57 . (canceled) 
     
     
         58 . A method for the screening of a SDF-1 antagonist or a SDF-1 agonist comprising the following steps:
 providing a candidate SDF-1 antagonist and/or a candidate SDF-1 agonist,   providing said nucleic acid molecule according to  claim 1 ,   providing a test system which provides a signal in the presence of a SDF-1 antagonist and/or a SDF-1 agonist, and   determining whether the candidate SDF-1 antagonist is a SDF-1 antagonist and/or whether the candidate SDF-1 agonist is a SDF-1 agonist.   
     
     
         59 . A method for the screening of a SDF-1 agonist and/or a SDF-1 antagonist comprising the following steps:
 providing SDF-1 immobilised to a phase,   providing said nucleic acid molecule according to  claim 1 , labelled,   adding a candidate SDF-1 agonist and/or a candidate SDF-1 antagonist, and   determining whether the candidate SDF-1 agonist is a SDF-1 agonist and/or whether the candidate SDF-1 antagonist is a SDF-1 antagonist.   
     
     
         60 .- 62 . (canceled)